Levalbuterol HCL Solution
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Amendment 0005 is issued to extend the closing date from April 04, 2022 to April 18, 2022 3:00 PM EDT (Eastern Daylight Time)
Amendment 0004 is issued to extend the closing date from March 21, 2022 to April 04, 2022 3:00 PM EDT (Eastern Daylight Time)
Amendment 0003 is issued to add the 30 count Vials per case to subject solicitation and amend solicitation pages as an attachment.
Amendment 0002 is issued to extend the closing date from March 07, 2022 to March 21, 2022 3:00 PM EDT (Eastern Daylight Time)
Amendment 0001 issued to solicitation for SPE2D2-21-R-0116 Levalbuterol HCL Solution to add (MG) Milligrams to the unit item description.
SPE2D2-21-R-0116 Levalbuterol HCL Solution Solicitation